SalivaTech's Saliva Cancer Risk Test "SalivaChecker®" Utilized in Health Promotion Collaboration Between Tsubame City, Niigata Prefecture and Nippon Life

SalivaTech Co., Ltd. conducted awareness activities for its saliva cancer risk test, "SalivaChecker®," at the "Tsubame JOY Health Festival" as part of a health promotion partnership between Tsubame City, Niigata Prefecture, and Nippon Life Insurance Company. This initiative aims to improve citizens' health awareness and contribute to early disease detection.
提携NQ 41/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 8, 2026 at 01:00
  • 🔍 Collected: May 7, 2026 at 16:31
  • 🤖 AI Analyzed: May 7, 2026 at 16:58 (26 min after Collected)
SalivaTech Co., Ltd. (Headquarters: Tsuruoka City, Yamagata Prefecture; Representative Director: Makoto Sunamura) announced that its saliva cancer risk test, "SalivaChecker®," was utilized in a health promotion and disease prevention partnership agreement concluded between Tsubame City, Niigata Prefecture, and Nippon Life Insurance Company (hereinafter "Nippon Life"). Awareness activities aimed at improving citizens' health consciousness were carried out through the "Tsubame JOY Health Festival" held on Sunday, March 8, at Yoshida Sangyo Kaikan (14-12 Yoshida Toei-cho, Tsubame City, Niigata Prefecture) to commemorate the 20th anniversary of the merger. Background and History Tsubame City and Nippon Life's Niigata Branch have been promoting comprehensive collaboration aimed at extending the healthy life expectancy of citizens and revitalizing the region. As a partner of Nippon Life, our company was invited to participate in their health promotion event, exhibiting a health check booth utilizing measurement devices and testing technologies. Through a crossword puzzle, we introduced "SalivaChecker®," a saliva-based cancer risk test. Saliva-based Cancer Risk Test "SalivaChecker®" "SalivaChecker®" is a test that evaluates cancer risk by analyzing metabolites in saliva and interpreting them with AI. It can assess the risk of 5 types of cancer for men (pancreatic, lung, stomach, colorectal, and oral cancer) and 6 types for women (the above plus breast cancer) in a single test. It was developed based on research results from Keio University's Institute for Advanced Biosciences. Over 110,000 people have used it to date. SalivaTech's Mission * Contribute to early disease detection and early intervention through screening test business. * Propose mechanisms to society that protect people's "lives" and "bodies" as a bridge between self-care and medical care. * Collaborate with academia to promote continuous technological development and clinical research, and quickly return results to society. [SalivaTech Overview] Company Name: SalivaTech Co., Ltd. Representative Director: Makoto Sunamura Business Activities: * Saliva-based cancer risk testing business * New risk test development business * Research testing contract business Corporate Website: https://salivatech.co.jp/ Service Website: https://sc.salivatech.co.jp/ SalivaTech Co., Ltd. E-mail: info@salivatech.co.jp Keywords: